Moderna Inc (MRNA)

[axelvento]

The trial results were impressive:
On Jan. 17, Moderna announced that its RSV vaccine was highly effective in phase 3 trials in preventing the risk of lower respiratory disease (where there were at least two symptoms) in people aged 60 and over. The rate of efficacy was 83.7%. That's slightly higher than the 82.6% efficacy that GSK reported from its vaccine in October, and well above the 66.7% that rival Pfizer achieved when it announced its trial results a few months earlier in August.


The RSV market is an attractive one. Morgan Stanley analysts project that it could be worth between $7 billion and $10 billion....